The efficacy of angiogenesis inhibitors combined with chemotherapy in advanced breast cancer: a systematic review and meta-analysis - Summary - MDSpire

The efficacy of angiogenesis inhibitors combined with chemotherapy in advanced breast cancer: a systematic review and meta-analysis

  • By

  • Jiangzhuo Wu

  • Hanbing Li

  • Ling Wei

  • Xiao Yan

  • Jiang Fang

  • Lin Peng

  • Xiaobo Zhao

  • June 5, 2026

  • 0 min

Share

Objective:

To evaluate the effectiveness of combining angiogenesis inhibitors with chemotherapy in advanced breast cancer.

Key Findings:
  • Adding angiogenesis inhibitors significantly improved PFS (HR 0.75), ORR, CBR, and DCR (all P<0.001).
  • No significant improvement in OS (HR 0.95, P = 0.171).
  • PFS benefit varied by subtype: mAbs outperformed TKIs in TNBC (HR 0.59 vs. 0.75); TKIs trended better in HR+ disease (HR 0.67).
  • Increased safety risks included hypertension (OR 4.59), thrombocytopenia (OR 4.54), proteinuria (OR 2.38), hand-foot syndrome (OR 2.14), and diarrhea (OR 1.97).
Interpretation:

The addition of angiogenesis inhibitors to chemotherapy improves PFS and response rates in advanced breast cancer, particularly in specific subtypes, but does not enhance overall survival.

Limitations:
  • Comparative efficacy across drug classes and optimal patient selection remain undefined.
  • Increased toxicity may limit treatment options and necessitate proactive management.
Conclusion:

Adding angiogenesis inhibitors to chemotherapy improves PFS and response in advanced breast cancer, especially in TNBC and HR+ disease, but does not affect OS.

Original Source(s)

Related Content